Displaying drugs 626 - 650 of 11635 in total
Disopyramide
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Matched Description: … membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar ... A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac …
Levocabastine
Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
Approved
Investigational
Matched Description: … Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis …
Cipaglucosidase alfa
Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … a deficiency in GAA. ... Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. ... Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated …
Piperaquine
Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative DB11638 as part of...
Approved
Experimental
Investigational
Sotalol
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous ... Sotalol is a methanesulfonanilide developed in 1960. …
Matched Categories: … Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …
Matched Categories: … Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …
Encainide
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Approved
Investigational
Withdrawn
Matched Description: … associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a …
Velaglucerase alfa
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Description: … Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. ... Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of …
Pegunigalsidase alfa
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term ... a different glycosylation pattern. ... the deficiency of alpha-galactosidase A. …
Ciclopirox
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a …
Nomifensine
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … FDA published a notice of its determination that Merital capsules were removed from the market for safety …
Febuxostat
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout...
Approved
Matched Description: … Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. ... a post-market clinical study (the CARES trial) where there was an increased risk of cardiovascular ( ... [A230548]
In February 2019, a black box warning for febuxostat was added, based on the findings of …
Phylloquinone
Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II,...
Approved
Investigational
Matched Description: … Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin. ... [L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates …
Nilotinib
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment ... found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a ... A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Acer rubrum pollen
Acer rubrum pollen is the pollen of the Acer rubrum plant. Acer rubrum pollen is mainly used in allergenic testing.
Approved
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Remoxipride
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 ... In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Famtozinameran
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. …
Vilazodone
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain . Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Approved
Matched Description: … Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine …
Deflazacort
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label]
Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular …
Treprostinil
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment...
Approved
Investigational
Matched Description: … Treprostinil is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of ... [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin …
Ledipasvir
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a …
Displaying drugs 626 - 650 of 11635 in total